123 related articles for article (PubMed ID: 27758886)
1. Targeting BRK-Positive Breast Cancers with Small-Molecule Kinase Inhibitors.
Jiang J; Gui F; He Z; Li L; Li Y; Li S; Wu X; Deng Z; Sun X; Huang X; Huang W; Han S; Zhang T; Wang Z; Jiao B; Song S; Wang H; Chen L; Zhou D; Liu Q; Ren R; Zhang J; Deng X
Cancer Res; 2017 Jan; 77(1):175-186. PubMed ID: 27758886
[TBL] [Abstract][Full Text] [Related]
2. Breast tumor kinase phosphorylates p190RhoGAP to regulate rho and ras and promote breast carcinoma growth, migration, and invasion.
Shen CH; Chen HY; Lin MS; Li FY; Chang CC; Kuo ML; Settleman J; Chen RH
Cancer Res; 2008 Oct; 68(19):7779-87. PubMed ID: 18829532
[TBL] [Abstract][Full Text] [Related]
3. Marine natural products-inspired phenylmethylene hydantoins with potent in vitro and in vivo antitumor activities via suppression of Brk and FAK signaling.
Sallam AA; Mohyeldin MM; Foudah AI; Akl MR; Nazzal S; Meyer SA; Liu YY; El Sayed KA
Org Biomol Chem; 2014 Jul; 12(28):5295-303. PubMed ID: 24927150
[TBL] [Abstract][Full Text] [Related]
4. Tracing the footprints of the breast cancer oncogene BRK - Past till present.
Goel RK; Lukong KE
Biochim Biophys Acta; 2015 Aug; 1856(1):39-54. PubMed ID: 25999240
[TBL] [Abstract][Full Text] [Related]
5. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
[TBL] [Abstract][Full Text] [Related]
6. Optimization, pharmacophore modeling and 3D-QSAR studies of sipholanes as breast cancer migration and proliferation inhibitors.
Foudah AI; Sallam AA; Akl MR; El Sayed KA
Eur J Med Chem; 2014 Feb; 73():310-24. PubMed ID: 24487236
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 4-anilino α-carbolines as novel Brk inhibitors.
Mahmoud KA; Krug M; Wersig T; Slynko I; Schächtele C; Totzke F; Sippl W; Hilgeroth A
Bioorg Med Chem Lett; 2014 Apr; 24(8):1948-51. PubMed ID: 24650640
[TBL] [Abstract][Full Text] [Related]
8. Molecular regulation of apoptotic machinery and lipid metabolism by mTORC1/mTORC2 dual inhibitors in preclinical models of HER2+/PIK3CAmut breast cancer.
Qian J; Chen Y; Meng T; Ma L; Meng L; Wang X; Yu T; Zask A; Shen J; Yu K
Oncotarget; 2016 Oct; 7(41):67071-67086. PubMed ID: 27563814
[TBL] [Abstract][Full Text] [Related]
9. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
[TBL] [Abstract][Full Text] [Related]
10. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
11. Putting the BRK on breast cancer: From molecular target to therapeutics.
Ang HL; Yuan Y; Lai X; Tan TZ; Wang L; Huang BB; Pandey V; Huang RY; Lobie PE; Goh BC; Sethi G; Yap CT; Chan CW; Lee SC; Kumar AP
Theranostics; 2021; 11(3):1115-1128. PubMed ID: 33391524
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of breast cancer metastases by a novel inhibitor of TGFβ receptor 1.
Fang Y; Chen Y; Yu L; Zheng C; Qi Y; Li Z; Yang Z; Zhang Y; Shi T; Luo J; Liu M
J Natl Cancer Inst; 2013 Jan; 105(1):47-58. PubMed ID: 23178439
[TBL] [Abstract][Full Text] [Related]
13. Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells.
Ostrander JH; Daniel AR; Lofgren K; Kleer CG; Lange CA
Cancer Res; 2007 May; 67(9):4199-209. PubMed ID: 17483331
[TBL] [Abstract][Full Text] [Related]
14. Small molecule inhibitors reveal PTK6 kinase is not an oncogenic driver in breast cancers.
Qiu L; Levine K; Gajiwala KS; Cronin CN; Nagata A; Johnson E; Kraus M; Tatlock J; Kania R; Foley T; Sun S
PLoS One; 2018; 13(6):e0198374. PubMed ID: 29879184
[TBL] [Abstract][Full Text] [Related]
15. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.
Guix M; Granja Nde M; Meszoely I; Adkins TB; Wieman BM; Frierson KE; Sanchez V; Sanders ME; Grau AM; Mayer IA; Pestano G; Shyr Y; Muthuswamy S; Calvo B; Krontiras H; Krop IE; Kelley MC; Arteaga CL
J Clin Oncol; 2008 Feb; 26(6):897-906. PubMed ID: 18180460
[TBL] [Abstract][Full Text] [Related]
16. Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.
Ferreira RB; Wang M; Law ME; Davis BJ; Bartley AN; Higgins PJ; Kilberg MS; Santostefano KE; Terada N; Heldermon CD; Castellano RK; Law BK
Oncotarget; 2017 Apr; 8(17):28971-28989. PubMed ID: 28423644
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic variant RON160 expression in breast cancer and its potential as a therapeutic target by small molecule tyrosine kinase inhibitor.
Yao HP; Zhuang CM; Zhou YQ; Zeng JY; Zhang RW; Wang MH
Curr Cancer Drug Targets; 2013 Jul; 13(6):686-97. PubMed ID: 23597200
[TBL] [Abstract][Full Text] [Related]
18. Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors).
Hirokawa Y; Levitzki A; Lessene G; Baell J; Xiao Y; Zhu H; Maruta H
Cancer Lett; 2007 Jan; 245(1-2):242-51. PubMed ID: 16540233
[TBL] [Abstract][Full Text] [Related]
19. Brk/PTK6 cooperates with HER2 and Src in regulating breast cancer cell survival and epithelial-to-mesenchymal transition.
Ai M; Liang K; Lu Y; Qiu S; Fan Z
Cancer Biol Ther; 2013 Mar; 14(3):237-45. PubMed ID: 23291984
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models.
Suzuki T; Fujii A; Ohya J; Nakamura H; Fujita F; Koike M; Fujita M
Cancer Sci; 2009 Aug; 100(8):1526-31. PubMed ID: 19459856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]